Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

CLLS has been the topic of several other research reports. Oppenheimer decreased their price target on Cellectis from $11.00 to $10.00 and set an outperform rating on the stock in a report on Wednesday, June 12th. JMP Securities reissued a market outperform rating and issued a $6.00 target price on shares of Cellectis in a research note on Friday, May 31st.

Cellectis Stock Performance

Shares of NASDAQ:CLLS opened at $2.26 on Wednesday. The firm has a fifty day simple moving average of $2.20 and a two-hundred day simple moving average of $2.42. Cellectis has a 52 week low of $0.96 and a 52 week high of $3.77. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $125.45 million, a P/E ratio of -1.75 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.05. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The company had revenue of $9.50 million during the quarter, compared to analyst estimates of $6.00 million. On average, analysts expect that Cellectis will post -0.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CLLS. Long Focus Capital Management LLC raised its holdings in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after buying an additional 130,000 shares during the period. Baillie Gifford & Co. grew its position in Cellectis by 1.3% in the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after acquiring an additional 10,605 shares during the last quarter. Principal Financial Group Inc. increased its stake in Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Cellectis during the second quarter worth $29,000. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.